What We’ve Learned in 9 Years.
For most of the last decade, clinicians couldn’t answer one question: “Will this probiotic work for my patient?” Here’s what nine years of data now lets us say.
Walk into any pharmacy and the probiotic shelf makes a hundred promises. Walk into a clinic and you’ll find most providers quietly skeptical — not because they doubt the microbiome matters, but because they couldn’t answer the only question that counts at the point of care: will this work for the person in front of me?
We started in 2015 with a different idea: don’t guess from strain claims in unrelated studies. Sequence the patient, formulate against what their microbiome actually shows, and — this is the part almost nobody does — follow up. Record what happened. Do it again, for nine years, across thousands of patients. Pair the before with the after.
That dataset is now big enough, and longitudinal enough, to say something real. So we’re saying it.
What the data now says
What it means for clinicians
It means the answer to “will this work for my patient?” is no longer a shrug. When you submit a patient’s microbiome data, we can match it against the patients who looked like them and the formulations they were given. In real-world follow-up, many patients report symptom improvement across successive formulation cycles, and retesting can show microbiome change. Because there is no control arm, we do not publish condition-level efficacy percentages — these observations are hypothesis-generating, not proof of efficacy. Many patients also present across two or more body systems, which is why the data supports layering and multi-formula recommendations rather than forcing one blunt product.
This is real-world, observational evidence — we’re explicit about its limits below. But it’s evidence that exists, at a scale we believe is rare in this category, and it’s the foundation under every formulation Flore Clinical generates.
We’re putting our work out for scrutiny.
Confidence in medicine is earned through transparency. We’re sharing the findings, publishing the methods, and inviting MDs, researchers, and academic partners to review the white paper and challenge the work — including the controlled trials now in development for The Regular One and The Bright One.
Become a peer reviewer / partner → Read the white paper →Put it to work for a patient
Join the provider portal to match a patient against everyone who looked like them and order the formulation that follows — or talk to us about what we’ve learned.
Join the Provider Portal → Talk to us / book a call →